DANVERS, Mass., Feb. 28 /PRNewswire-FirstCall/ -- ABIOMED, Inc. announced today that it will be presenting at the SG Cowen & Co. 26th Annual Healthcare Conference on March 6, 2006 at 4:00 p.m. ET. The conference will be held at the Boston Marriott Copley Place Hotel.
Michael Minogue, ABIOMED Chairman, Chief Executive Officer and President, will provide an overview of the Company and discuss its strategic objectives for driving growth.
ABOUT ABIOMED
Based in Danvers, Massachusetts, ABIOMED, Inc. (pronounced “AB'-EE-O-MED”) is a leading developer, manufacturer and marketer of medical products designed to assist or replace the pumping function of the failing heart. ABIOMED currently manufactures and sells the AB5000(TM) Circulatory Support System and the BVS(R) 5000 Biventricular Support System for the temporary support of all patients with failing but potentially recoverable hearts. In Europe, ABIOMED offers the IMPELLA(R) RECOVER(R) minimally invasive cardiovascular support systems under CE Mark approval. The Company’s AbioCor(R) Implantable Replacement Heart was the subject of an initial clinical trial under an Investigational Device Exemption from the United States Food and Drug Administration. The AbioCor has not been approved for commercial distribution, and is not available for use or sale outside of the initial clinical trial. For additional information please visit: http://www.abiomed.com.
Media Contact: Liza Heapes ABIOMED, INC. Media Relations (978) 646-1668 mediarelations@abiomed.com Daniel Sutherby ABIOMED, INC. Chief Financial Officer (978) 646-1812 ir@abiomed.com FORWARD-LOOKING STATEMENTS
This Release contains forward-looking statements, including statements regarding development of ABIOMED’s existing and new products, the Company’s progress toward commercial growth, and future opportunities. The Company’s actual results may differ materially from those anticipated in these forward- looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing and other risks and challenges detailed in the Company’s filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.
ABIOMED, Inc.
CONTACT: Liza Heapes, Media Relations, +1-978-646-1668,mediarelations@abiomed.com, or Daniel Sutherby, Chief Financial Officer,+1-978-646-1812, ir@abiomed.com, both of ABIOMED, Inc.
Web site: http://www.abiomed.com/
